JP2019089842A - 頭痛予防用組成物 - Google Patents
頭痛予防用組成物 Download PDFInfo
- Publication number
- JP2019089842A JP2019089842A JP2019032510A JP2019032510A JP2019089842A JP 2019089842 A JP2019089842 A JP 2019089842A JP 2019032510 A JP2019032510 A JP 2019032510A JP 2019032510 A JP2019032510 A JP 2019032510A JP 2019089842 A JP2019089842 A JP 2019089842A
- Authority
- JP
- Japan
- Prior art keywords
- cysteine
- composition
- composition according
- glutathione
- acetaldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 161
- 206010019233 Headaches Diseases 0.000 title abstract description 18
- 231100000869 headache Toxicity 0.000 title abstract description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 84
- 239000013543 active substance Substances 0.000 claims abstract description 51
- 108010024636 Glutathione Proteins 0.000 claims abstract description 42
- 229960003180 glutathione Drugs 0.000 claims abstract description 42
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 36
- 229960003067 cystine Drugs 0.000 claims abstract description 36
- 229930182817 methionine Natural products 0.000 claims abstract description 36
- 229960004452 methionine Drugs 0.000 claims abstract description 36
- 208000006561 Cluster Headache Diseases 0.000 claims abstract description 28
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 15
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims abstract description 11
- 229930195710 D‐cysteine Natural products 0.000 claims abstract description 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 11
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 11
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 9
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 150000001944 cysteine derivatives Chemical class 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 164
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Natural products SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 62
- 235000018417 cysteine Nutrition 0.000 claims description 54
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 52
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 42
- 235000013305 food Nutrition 0.000 claims description 40
- 210000002784 stomach Anatomy 0.000 claims description 40
- 239000003826 tablet Substances 0.000 claims description 32
- 230000000391 smoking effect Effects 0.000 claims description 31
- 235000013361 beverage Nutrition 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 23
- 210000003296 saliva Anatomy 0.000 claims description 21
- -1 cysteine compound Chemical class 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- 208000018316 severe headache Diseases 0.000 claims description 18
- 239000000654 additive Substances 0.000 claims description 17
- 229940112822 chewing gum Drugs 0.000 claims description 17
- 235000015218 chewing gum Nutrition 0.000 claims description 17
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 16
- 239000000945 filler Substances 0.000 claims description 16
- 239000000796 flavoring agent Substances 0.000 claims description 16
- 235000019634 flavors Nutrition 0.000 claims description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 235000003599 food sweetener Nutrition 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 12
- 239000003765 sweetening agent Substances 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000004201 L-cysteine Substances 0.000 claims description 10
- 235000013878 L-cysteine Nutrition 0.000 claims description 10
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 206010027599 migraine Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 claims description 8
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 claims description 8
- 229960001340 histamine Drugs 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 239000006189 buccal tablet Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 239000006190 sub-lingual tablet Substances 0.000 claims description 6
- 150000008163 sugars Chemical class 0.000 claims description 6
- 229960003080 taurine Drugs 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229940046011 buccal tablet Drugs 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920002521 macromolecule Polymers 0.000 claims description 5
- 229940098466 sublingual tablet Drugs 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 150000002605 large molecules Chemical class 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 229920001206 natural gum Polymers 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000000779 smoke Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229920003052 natural elastomer Polymers 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229950005134 polycarbophil Drugs 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- XOTREVBPKJHQEX-UHFFFAOYSA-M sodium;2-(3,3,6,6-tetramethyl-1,8-dioxo-9-phenyl-4,5,7,9-tetrahydro-2h-acridin-10-yl)acetate Chemical compound [Na+].C1C(C)(C)CC(=O)C2=C1N(CC([O-])=O)C(CC(C)(C)CC1=O)=C1C2C1=CC=CC=C1 XOTREVBPKJHQEX-UHFFFAOYSA-M 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 2
- 230000009747 swallowing Effects 0.000 claims description 2
- 229920003051 synthetic elastomer Polymers 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000004606 Fillers/Extenders Substances 0.000 claims 1
- 244000043261 Hevea brasiliensis Species 0.000 claims 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 229920000831 ionic polymer Polymers 0.000 claims 1
- 239000013563 matrix tablet Substances 0.000 claims 1
- 235000020939 nutritional additive Nutrition 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 206010027603 Migraine headaches Diseases 0.000 abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 74
- 235000019441 ethanol Nutrition 0.000 description 48
- 230000000694 effects Effects 0.000 description 23
- 210000000214 mouth Anatomy 0.000 description 22
- 108010066264 gastrin 17 Proteins 0.000 description 17
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 17
- 208000004300 Atrophic Gastritis Diseases 0.000 description 15
- 208000036495 Gastritis atrophic Diseases 0.000 description 15
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 15
- 206010010904 Convulsion Diseases 0.000 description 13
- 239000001856 Ethyl cellulose Substances 0.000 description 13
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 13
- 235000019325 ethyl cellulose Nutrition 0.000 description 13
- 229920001249 ethyl cellulose Polymers 0.000 description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 235000019504 cigarettes Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 101710198144 Endopolygalacturonase I Proteins 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000711 cancerogenic effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 241000208125 Nicotiana Species 0.000 description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 6
- 229930003779 Vitamin B12 Natural products 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 235000019163 vitamin B12 Nutrition 0.000 description 6
- 239000011715 vitamin B12 Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 235000019505 tobacco product Nutrition 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 4
- 229920003137 Eudragit® S polymer Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 4
- 231100000315 carcinogenic Toxicity 0.000 description 4
- 230000001055 chewing effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 4
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- FHTPNEYXMGZOSH-UHFFFAOYSA-N 2-methyl-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound CC1NC(C(O)=O)CS1 FHTPNEYXMGZOSH-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 102400000921 Gastrin Human genes 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 description 3
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108010092028 endopolygalacturonase II Proteins 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 3
- 229920003176 water-insoluble polymer Polymers 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108010047320 Pepsinogen A Proteins 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000019506 cigar Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229960001186 methysergide Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 1
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 244000239659 Eucalyptus pulverulenta Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108090001072 Gastricsin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241001417501 Lobotidae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 208000018238 Primary Headache disease Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- CXJAAWRLVGAKDV-UHFFFAOYSA-N acetyltaurine Chemical compound CC(=O)NCCS(O)(=O)=O CXJAAWRLVGAKDV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229960001903 ergotamine tartrate Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000004478 pupil constriction Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020046 sherry Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03022—Diamine oxidase (1.4.3.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、活性成分としてL-システイン、D-システイン、およびN-アセチルシステインからなる群から選ばれる1またはそれ以上のシステイン化合物を、1またはそれ以上のさらなる活性物質であって、少なくともその1がシスチン、グルタチオン、およびメチオニンから選ばれる活性物質と組み合わせて含む、重度の頭痛を予防するかまたはその発生を減少させるための経口投与用の非毒性固体医薬組成物に関する。
本発明の態様によれば、該組成物はさらに過剰なヒスタミンを分解するための活性成分としてジアミンオキシダーゼ(すなわちヒスタミナーゼ)を含む。
(定義)
本発明の組成物は、活性物質として、L-システイン、D-システイン、およびN-アセチルシステインの群から選ばれる1またはそれ以上の物質を、先に記載のあらゆる形のシスチン、グルタチオン、およびメチオニンから選ばれる1またはそれ以上の物質との混合物として含み、所望によりさらなる活性物質を含む。
1. 医薬的に許容される希釈剤(充填剤、増量剤)、
2. 甘味料、例えば糖および糖アルコール、
3. 香味料、および
4. スリップ添加物/潤滑剤。
システイン 2〜10mg
シスチン/グルタチオン/メチオニン 2〜10mg
希釈剤/甘味料 50〜750mg
香味料 q.s.
潤滑剤(0.5〜3重量%) 5〜25mg
システイン 2〜10mg
シスチン/グルタチオン/メチオニン 2〜10mg
ガムベース
(例えば甘味料を含む) 500〜1500mg
香味料 q.s.
潤滑剤(0.5〜3重量%) 5〜30mg
システイン 2〜10mg
シスチン/グルタチオン/メチオニン 2〜10mg
非イオン性大分子 5〜25mg
イオン化大分子 2〜10mg
香味料 q.s.
潤滑剤 0.5〜3重量%
システイン 2〜10mg
シスチン/グルタチオン/メチオニン 2〜10mg
希釈剤/甘味料 q.s. 50〜500mg
香味料 q.s.
潤滑剤 0.5〜3重量%
システイン 5〜40w-%(好ましくは25w-%)
シスチン/グルタチオン/メチオニン 5〜40w-%(好ましくは25w-%)
胃の中で溶解しないポリマー 10〜50w-%(好ましくは20〜30w-%)
不活性充填剤 20〜70w-%(好ましくは40〜60w-%)
エタノール q.s.。
システイン 5〜40w-%(好ましくは25w-%)
シスチン/グルタチオン/メチオニン 5〜40w-%(好ましくは25w-%)
胃の中で溶解しないポリマー 10〜50w-%(好ましくは20〜30w-%)
不活性充填剤 20〜70w-%(好ましくは20〜50w-%)
システイン 1〜50w-%(好ましくは20〜50w-%)
シスチン/グルタチオン/メチオニン 1〜50w-%(好ましくは20〜50w-%)
水溶性充填剤 50〜80w-%(好ましくは30〜60w-%)
多孔質膜形成剤 q.s.。
(処置)
a) 少なくとも時々重度の頭痛に罹るヒト対象に、アルコール飲料または食品、またはアセトアルデヒド含有飲料または食品の摂取に際して、または喫煙に際して投与するシステインおよびシスチン、またはグルタチオン、またはメチオニンを含む組成物を提供し、
b) 該対象が該組成物を自己投与し、および
c) 該対象に食べさせ、飲ませ、または喫煙させ、システインおよびシスチン、またはグルタチオンまたはメチオニンが、飲料または食品の摂取に際して体内に生じるかまたは運ばれたアセトアルデヒドと結合する、
d) 所望により、工程a)〜c)を必要と感じる回数反復する。
本発明のある態様では、本発明の組成物は、重度の頭痛への罹患に加えて萎縮性胃炎を有するヒト対象に投与される。
なめる錠剤(1タイプは以下のものを含む)を製造した。
L-システイン 20mg
シスチン 20mg
マンニトール(または等価な糖または糖アルコール) 750mg
香味料 q.s.
ステアリン酸マグネシウム 10mg
さらなる組成物はシステイン含有量が1.25mg、2.5mg、5mg、および10mgシステインと変化した。
粉末を混合し、それをなめる錠剤に圧縮して該組成物を製造した。
以下を含むチューインガムを製造した。
システイン 20mg
シスチン 20mg
Pharmagum S、M、またはC 1000mg
香味料 q.s.
ステアリン酸マグネシウム 20mg
粉末を混合し、それをチューインガムに圧縮して該組成物を製造した。
500mgのPharmagum SまたはM、および20mgのステアリン酸マグネシウムを含む別の組成物を製造した。
以下を含むバッカル錠を製造した。
システイン 20mg
シスチン 20mg
Methocel 25mg
Carbopol 7mg
香味料 q.s.
ステアリン酸マグネシウム 2mg
粉末を混合し、それをバッカル錠に圧縮して該組成物を製造した。
以下を含む舌下錠を製造した。
システイン 10mg
シスチン 10mg
マンニトール 250mg
香味料 q.s.
ステアリン酸マグネシウム 5mg
粉末を混合し、それを舌下錠に圧縮して該組成物を製造した。
5人の喫煙者(年齢29±2.8)が試験に参加し、3本のシガレットを吸った(間に浄化期間を設けた)。各シガレット(5分間)を喫煙中に、ボランティアは、それぞれプラセボ、または1.25mg、2.5mg、5mg、10mg、または20mgのL-システインを含む錠剤を盲検的になめた。唾液試料中のアセトアルデヒドを、喫煙開始から0、5、10、20分間後にガスクロマトグラフィにより分析した。
該試験は、溶解する錠剤で送達すると5mgのL-システインでも喫煙中の唾液中の発癌性アセトアルデヒドを完全に不活化することを示した。1.25mgのL-システイン錠は、アセトアルデヒドの量をプラセボに比べて約3分の2減少させた。
たばこの煙は喫煙中に唾液に溶解するアセトアルデヒドを含む(図2参照)。この試験において、喫煙者と非喫煙者は共に、最初に少量のアルコールを摂取し、次いで喫煙者は約5分間毎に6本シガレットを吸った。喫煙中の唾液のアセトアルデヒドは発癌レベルを著しく超える。
アルコールまたは喫煙由来の唾液のアセトアルデヒドは、飲み込むと口腔内から咽頭、食道、および胃に分散する。したがって、発癌作用は口に限定されない。
ALDH2欠損対象(フラッシャー)においてさらなる唾液のアセトアルデヒドは唾液腺由来と思われた。
アジア諸国での種々の疫学的研究は、ALDH2欠損が上部消化器癌の10倍以上のリスクと関連があることを一様に示した。該関連は、大量飲酒者で最も大きいが、さらに通常のアルコール消費者でも顕著である。したがって、喫煙者も明らかにリスクが高い。
結論として、たばこ由来のアセトアルデヒドは、用量依存性および相乗的に上部消化管で局所的発癌物質として作用すると思われる。
システインは硫黄を含むアミノ酸である。その平均摂取量は約1g/日である。システインは反応性および発癌性アセトアルデヒドと縮合し、2−メチル−チアゾリジン−4−カルボン酸(MTCA)を形成することによりそれを不活化する。
例えば、わずか5mgのL-またはD-システインを含むトローチ剤は、喫煙中の唾液からアセトアルデヒドを完全に除去する(図3)。
反応性アセトアルデヒドの有害作用は、それがシステインと結合することにより防ぐことができる。この準必須アミノ酸は、非酵素的結合によってより安定な化合物の2-メチルチアゾリジン-4-カルボン酸を形成することにより不活化する。例えば、L-システインを含む錠剤およびチューインガムが喫煙中のアセトアルデヒドへの暴露を排除するために開発された(図4)。
Claims (25)
- 重度の頭痛を予防するかまたはその発生を減少させるための経口投与用の非毒性固体医薬組成物であって、
L-システイン、D-システイン、およびN-アセチルシステインの群から選ばれる1またはそれ以上のシステイン化合物を活性物質として含み、
該システイン化合物が、1またはそれ以上のさらなる活性物質と組み合わされ、
ここで、その少なくとも1は、シスチン、グルタチオン、およびメチオニンの群から選ばれる、
さらに、口の条件で唾液中に少なくとも5分間にわたり、または胃の条件で胃内に少なくとも15分間にわたり活性物質の制御放出をもたらす1またはそれ以上の非毒性担体を含む1またはそれ以上の医薬的添加物を含むことを特徴とする、組成物。 - 片頭痛または群発性頭痛、特に群発性頭痛を予防するかまたはその発生を減少させるための請求項1記載の組成物。
- 粉末剤、錠剤、トローチ剤、カプセル剤、またはチューインガムの形であることを特徴とする請求項1または2に記載の組成物。
- 該活性物質が、L-システイン、およびシスチン、グルタチオン、およびメチオニンの1またはそれ以上、好ましくはL-システインおよび後者の1から選ばれ、該後者は最も適切にはグルタチオンである、ことを特徴とする先の請求項のいずれかに記載の組成物。
- 1またはそれ以上のシステイン化合物およびグルタチオン、好ましくは1のシステイン化合物およびグルタチオンから選ばれ、前者は最も適切にはL-システインである、ことを特徴とする先の請求項のいずれかに記載の組成物。
- さらにジアミンオキシダーゼを過剰なヒスタミンを分解するための活性物質として含むことを特徴とする先の請求項のいずれかに記載の組成物。
- 該活性物質が、L-システイン、D-システイン、N-アセチルシステイン、シスチン、グルタチオン、およびメチオニンから選ばれるアミノ酸からなることを特徴とする請求項1〜5のいずれかに記載の組成物。
- さらにビタミン、もしくはタウリン化合物または一般的水溶性ビタミン、例えば、ビタミンC、B2、またはB5、またはその塩から選ばれる、好ましくはビタミンC、またはタウリンの塩、例えばマグネシウムまたはカルシウム塩から選ばれ、より好ましくはマグネシウムタウリネートから選ばれる、同様の栄養的添加物、を含む、該添加物が最も適切にはマグネシウムN-アセチルタウリネートである、ことを特徴とする、先の請求項のいずれかに記載の組成物。
- 総量、2〜50mg/単位用量、好ましくは2〜20mg/単位用量、最も適切には4〜10mg/単位用量の、活性物質、特にシステイン化合物、およびさらなる活性物質を含むことを特徴とする先の請求項のいずれかに記載の組成物。
- 該活性物質を口または胃で制御放出するか、または摂取前に食品または飲料中に放出するために製剤化されることを特徴とする先の請求項のいずれかに記載の組成物。
- 該活性物質を口で放出するための製剤中のシステイン化合物の量が、2〜10mg/単位用量、好ましくは約5mgであり、該製剤中の、シスチン、またはグルタチオン、またはメチオニン、またはその組み合わせの量が、2〜10mg/単位用量、好ましくは約5mgであり、該活性物質を胃に放出するための該製剤中のシステインの量が、10〜50mg/単位用量、好ましくは約20mgであり、該製剤中のシスチン、またはグルタチオン、またはメチオニン、またはその組み合わせの量が、10〜50mg/単位用量、好ましくは約20mgであることを特徴とする請求項10記載の組成物。
- 添加物として、希釈剤、例えば充填剤または増量剤、甘味料、例えば糖または糖アルコール、香味料、潤滑剤、ガムベース、非イオン性ポリマー、またはイオン化ポリマー、またはこれらの2またはそれ以上の組み合わせを含むことを特徴とする先の請求項のいずれかに記載の組成物。
- ガムベースが、天然または合成エラストマー、軟化剤、ワックス、および脂質から選ばれ、天然ガムベースが、好ましくは生ゴムおよび燻煙天然ゴムから選ばれ、合成ガムベースが、好ましくはスチレンブタジエンゴム、ポリエチレン、およびポリ酢酸ビニルから選ばれることを特徴とする請求項12記載の組成物。
- 非イオン性ポリマーが、メチルセルロース(MC)、ヒドロキシプロピルセルロース(HPC)、およびヒドロキシプロピルメチルセルロース(HPMC)、およびポリエチレングリコール(PEG)から選ばれることを特徴とする請求項12記載の組成物。
- イオン化ポリマーが、カルボキシメチルセルロースナトリウム(NaCMC)、アルギン酸、アルギン酸ナトリウム、キトサン、ポリカルボフィル(Noveon(登録商標))、およびカルボマー(Capropol(登録商標))から選ばれることを特徴とする請求項12記載の組成物。
- 希釈剤が、ラクトース、リン酸カルシウム、デンプン、カルボキシメチルセルロース、ヒドロキシメチルセルロースから選ばれることを特徴とする請求項12記載の組成物。
- チューインガムに製剤化される、ガムベースが、チューインガムの15〜40%を構成し、残る部分が、薬用物質、糖、甘味料、軟化剤、香味料、および着色料から選ばれる物質を含むことを特徴とする先の請求項のいずれかに記載の組成物。
- 含有量40〜80w-%の非イオン性大分子および含有量20〜60w-%のイオン化ポリマーを含むバッカル錠に製剤化されていることを特徴とする請求項1〜16のいずれかに記載の組成物。
- 含有量90〜98w-%の希釈剤を含む舌下錠に製剤化されていることを特徴とする請求項1〜16のいずれかに記載の組成物。
- 含有量10〜50w-%の胃で溶解しないポリマーおよび含有量20〜70w-%の充填剤を含むマトリックス顆粒またはマトリックス錠に製剤化されていることを特徴とする請求項1〜16のいずれかに記載の組成物。
- 該組成物から製剤化した1または2製剤を同時に口の中に置き、4〜10時間間隔、最も好ましくは6〜8時間間隔で新しいものと交換することにより投与することを特徴とする先の請求項のいずれかに記載の組成物。
- 医薬として用いるための、L-システイン、D-システイン、およびN-アセチルシステインから選ばれる1またはそれ以上のシステイン化合物と、化合物シスチン、グルタチオン、およびメチオニンの1またはそれ以上との組み合わせ。
- 以下の工程を実施することを特徴とするヒト対象の重度の頭痛の発生を減少させる方法:
a) アルコール飲料または食品、またはアセトアルデヒド含有飲料または食品の摂取または喫煙に際して自己投与すべき少なくとも時々重度の頭痛に罹る患者に、請求項1〜20のいずれかに記載の組成物を提供し、
b) 該対象に該組成物を自己投与させ、
c) 該対象が食べ、飲み、または喫煙するのを許し、
それにより、該システイン、および該シスチン、または該グルタチオン、または該メチオニンが、該対象が飲料または食品を摂取するのに際して身体に生じまたは運ばれるアセトアルデヒドと結合し、
d) 所望により、工程a)〜c)を必要と感じる回数だけ反復する。 - 片頭痛または群発性頭痛を予防し、またはその発生を減少させるための請求項23記載の方法。
- 工程b)において、該組成物から製剤化した1または2製剤を口中に置くか、またはそれらを飲み込ませることにより該組成物を該対象に投与し、所望の工程d)を該製剤を4〜10時間間隔、最も好ましくは6〜8時間間隔で新しいものと交換することにより実施し、
所望により工程c)も反復することを特徴とする請求項23または24記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20125570A FI129157B (fi) | 2012-05-28 | 2012-05-28 | Koostumus käytettäväksi vakavien päänsärkyjen esiintymistiheyden pienentämiseksi tai niiden vähentämiseksi |
FI20125570 | 2012-05-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015514547A Division JP2015518038A (ja) | 2012-05-28 | 2013-05-28 | 頭痛予防用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019089842A true JP2019089842A (ja) | 2019-06-13 |
Family
ID=49672530
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015514547A Pending JP2015518038A (ja) | 2012-05-28 | 2013-05-28 | 頭痛予防用組成物 |
JP2019032510A Pending JP2019089842A (ja) | 2012-05-28 | 2019-02-26 | 頭痛予防用組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015514547A Pending JP2015518038A (ja) | 2012-05-28 | 2013-05-28 | 頭痛予防用組成物 |
Country Status (21)
Country | Link |
---|---|
US (1) | US10092534B2 (ja) |
EP (1) | EP2854792B1 (ja) |
JP (2) | JP2015518038A (ja) |
KR (1) | KR20150016382A (ja) |
CN (2) | CN104427983A (ja) |
AU (1) | AU2013269448B2 (ja) |
BR (1) | BR112014029165A2 (ja) |
CA (1) | CA2871127A1 (ja) |
DK (1) | DK2854792T3 (ja) |
ES (1) | ES2922243T3 (ja) |
FI (1) | FI129157B (ja) |
HK (2) | HK1208362A1 (ja) |
HU (1) | HUE059234T2 (ja) |
IL (1) | IL235972B (ja) |
JO (1) | JOP20130157B1 (ja) |
MX (1) | MX2014014609A (ja) |
PL (1) | PL2854792T3 (ja) |
PT (1) | PT2854792T (ja) |
RU (1) | RU2698196C2 (ja) |
TW (1) | TWI660726B (ja) |
WO (1) | WO2013178880A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI128082B (en) * | 2014-09-15 | 2019-09-13 | Biohit Oyj | Preparations for the treatment and prevention of alcohol redness and alcohol-induced hypersensitivity reactions |
FI127823B (en) * | 2015-03-06 | 2019-03-15 | Biohit Oyj | A composition for preventing the symptoms of a hangover |
WO2017004396A1 (en) * | 2015-06-30 | 2017-01-05 | Nucorplabs, Inc. | Chewable composition to deliver gsh |
BE1025644B1 (fr) * | 2017-10-13 | 2019-05-15 | Synapharm Industrial Synthesis | Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale |
JP7542530B2 (ja) * | 2018-11-02 | 2024-08-30 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 |
US20220218633A1 (en) * | 2019-05-16 | 2022-07-14 | Synapharm Industrial Synthesis | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036098A1 (en) * | 2000-10-30 | 2002-05-10 | Licentia Ltd | Method and preparation for binding acetaldehyde in saliva, stomach and large intestine |
WO2006037848A1 (en) * | 2004-10-08 | 2006-04-13 | Biohit Oyj | Method and preparation for binding aldehydes in saliva |
JP2006130488A (ja) * | 2004-11-02 | 2006-05-25 | Kazutoshi Igarashi | 新無機多孔体を利用した有害分子を吸着分解できる基剤 |
JP2007522254A (ja) * | 2004-02-17 | 2007-08-09 | マルクス グラフ ヴィ. マツーシュカ−グライフェンクラウ | アルコール代謝調節組成物 |
JP2009522376A (ja) * | 2006-01-06 | 2009-06-11 | アメリラブ テクノロジーズ,インコーポレイテッド | グアバ抽出物を使用する方法及びグアバ抽出物を含む組成物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496548A (en) | 1983-02-04 | 1985-01-29 | Moldowan Mervin J | Composition and method for reducing hangover |
US4528295A (en) | 1983-08-15 | 1985-07-09 | Boris Tabakoff | Composition and method for reducing blood acetaldehyde levels |
US5202354A (en) | 1986-02-18 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Composition and method for reducing acetaldehyde toxicity |
JPH02193926A (ja) * | 1989-01-20 | 1990-07-31 | Lion Corp | 胃腸薬 |
US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US5922346A (en) | 1997-12-01 | 1999-07-13 | Thione International, Inc. | Antioxidant preparation |
US6726939B1 (en) * | 2000-03-22 | 2004-04-27 | Kyoungsik Pak | Composition and method for reducing blood pressure, alleviating or eliminating angina pectoris and headaches, and enhancing skin and hair |
US6502038B1 (en) * | 2000-06-30 | 2002-12-31 | Exxonmobil Upstream Research Company | Method for non-hyperbolic moveout analysis of seismic data |
FI122914B (fi) * | 2005-04-01 | 2012-08-31 | Biohit Oyj | Elintarvikekoostumus asetaldehydin sitomiseksi suussa ja ruoansulatuskanavassa ja menetelmä koostumuksen valmistamiseksi |
FI20060501L (fi) * | 2006-05-22 | 2007-11-23 | Biohit Oyj | Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa |
JP2006328079A (ja) * | 2006-07-26 | 2006-12-07 | T Langeland Bjorn | 特定の金属酵素を刺激する組成物 |
US20080057110A1 (en) | 2006-08-29 | 2008-03-06 | Alexander Skirpa | Compositions for alcoholic beverages and methods of producing thereof |
US20080075710A1 (en) * | 2006-09-25 | 2008-03-27 | Liquid Potions Llc | Herbal composition for treating hangovers |
FI20070705L (fi) | 2007-09-14 | 2009-06-02 | Biohit Oyj | Asetaldehydin sitominen suussa ja mahalaukussa |
CN101862332A (zh) * | 2009-04-20 | 2010-10-20 | 兰章华 | 防治过量饮酒对人体损伤的组合物及其制备方法和用途 |
JP2011057674A (ja) | 2009-09-11 | 2011-03-24 | Omnica Gmbh | コエンザイムq−10と抗酸化剤とを含む組成物 |
EP2374448A1 (en) | 2010-04-06 | 2011-10-12 | Labtec GmbH | Oral film formulation |
WO2012027603A2 (en) * | 2010-08-26 | 2012-03-01 | Clarity Products, Limited Liability Company | Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2 |
-
2012
- 2012-05-28 FI FI20125570A patent/FI129157B/fi active IP Right Grant
-
2013
- 2013-05-22 JO JOP/2013/0157A patent/JOP20130157B1/ar active
- 2013-05-27 TW TW102118677A patent/TWI660726B/zh active
- 2013-05-28 BR BR112014029165A patent/BR112014029165A2/pt not_active Application Discontinuation
- 2013-05-28 EP EP13796555.4A patent/EP2854792B1/en active Active
- 2013-05-28 CN CN201380028125.9A patent/CN104427983A/zh active Pending
- 2013-05-28 KR KR1020147036794A patent/KR20150016382A/ko not_active Application Discontinuation
- 2013-05-28 HU HUE13796555A patent/HUE059234T2/hu unknown
- 2013-05-28 WO PCT/FI2013/050582 patent/WO2013178880A1/en active Application Filing
- 2013-05-28 PL PL13796555.4T patent/PL2854792T3/pl unknown
- 2013-05-28 PT PT137965554T patent/PT2854792T/pt unknown
- 2013-05-28 AU AU2013269448A patent/AU2013269448B2/en active Active
- 2013-05-28 MX MX2014014609A patent/MX2014014609A/es unknown
- 2013-05-28 US US14/397,563 patent/US10092534B2/en active Active
- 2013-05-28 CN CN201711384347.0A patent/CN108042520A/zh active Pending
- 2013-05-28 JP JP2015514547A patent/JP2015518038A/ja active Pending
- 2013-05-28 DK DK13796555.4T patent/DK2854792T3/da active
- 2013-05-28 RU RU2014143120A patent/RU2698196C2/ru active
- 2013-05-28 ES ES13796555T patent/ES2922243T3/es active Active
- 2013-05-28 CA CA2871127A patent/CA2871127A1/en not_active Abandoned
-
2014
- 2014-11-27 IL IL23597214A patent/IL235972B/en active IP Right Grant
-
2015
- 2015-09-17 HK HK15109090.3A patent/HK1208362A1/xx unknown
-
2018
- 2018-08-20 HK HK18110629.8A patent/HK1251161A1/zh unknown
-
2019
- 2019-02-26 JP JP2019032510A patent/JP2019089842A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036098A1 (en) * | 2000-10-30 | 2002-05-10 | Licentia Ltd | Method and preparation for binding acetaldehyde in saliva, stomach and large intestine |
JP2007522254A (ja) * | 2004-02-17 | 2007-08-09 | マルクス グラフ ヴィ. マツーシュカ−グライフェンクラウ | アルコール代謝調節組成物 |
WO2006037848A1 (en) * | 2004-10-08 | 2006-04-13 | Biohit Oyj | Method and preparation for binding aldehydes in saliva |
JP2006130488A (ja) * | 2004-11-02 | 2006-05-25 | Kazutoshi Igarashi | 新無機多孔体を利用した有害分子を吸着分解できる基剤 |
JP2009522376A (ja) * | 2006-01-06 | 2009-06-11 | アメリラブ テクノロジーズ,インコーポレイテッド | グアバ抽出物を使用する方法及びグアバ抽出物を含む組成物 |
Non-Patent Citations (3)
Title |
---|
PEATFIELD R., HEADACHE, JPN6018026829, 1986, pages 44 - 47, ISSN: 0004184956 * |
日本内科学会雑誌, vol. 第82巻,第3号, JPN6018048701, 1993, JP, pages 52 - 376, ISSN: 0004184958 * |
脳外誌, vol. 17巻,3号, JPN6018048700, 2008, JP, pages 234 - 241, ISSN: 0004184957 * |
Also Published As
Publication number | Publication date |
---|---|
MX2014014609A (es) | 2015-02-12 |
HUE059234T2 (hu) | 2022-10-28 |
HK1208362A1 (en) | 2016-03-04 |
IL235972B (en) | 2019-10-31 |
RU2698196C2 (ru) | 2019-08-23 |
AU2013269448B2 (en) | 2016-02-11 |
WO2013178880A1 (en) | 2013-12-05 |
HK1251161A1 (zh) | 2019-01-25 |
JOP20130157B1 (ar) | 2021-08-17 |
JP2015518038A (ja) | 2015-06-25 |
FI20125570L (fi) | 2013-11-29 |
FI129157B (fi) | 2021-08-13 |
EP2854792A1 (en) | 2015-04-08 |
US10092534B2 (en) | 2018-10-09 |
CN108042520A (zh) | 2018-05-18 |
RU2014143120A (ru) | 2016-07-20 |
EP2854792B1 (en) | 2022-06-15 |
TW201408286A (zh) | 2014-03-01 |
PT2854792T (pt) | 2022-07-13 |
CN104427983A (zh) | 2015-03-18 |
US20150132275A1 (en) | 2015-05-14 |
EP2854792A4 (en) | 2015-11-18 |
DK2854792T3 (da) | 2022-07-11 |
CA2871127A1 (en) | 2013-12-05 |
PL2854792T3 (pl) | 2022-10-03 |
KR20150016382A (ko) | 2015-02-11 |
BR112014029165A2 (pt) | 2017-06-27 |
ES2922243T3 (es) | 2022-09-12 |
IL235972A0 (en) | 2015-01-29 |
TWI660726B (zh) | 2019-06-01 |
AU2013269448A1 (en) | 2014-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019089842A (ja) | 頭痛予防用組成物 | |
US9161909B2 (en) | Adhesive compositions for the treatment of xerostomia | |
EP1976544B1 (en) | Method of using guava extract and composition including guava extract | |
US7776831B2 (en) | Use of antifungal compositions to treat upper gastrointestinal conditions | |
US5741805A (en) | Controlled release pilocarpine delivery system | |
CA2678500A1 (en) | Compositions and methods for enhancing transmucosal delivery | |
EA019832B1 (ru) | Применение композиции и способ связывания ацетальдегида в желудке | |
JP4691312B2 (ja) | 唾液、胃、大腸におけるアセトアルデヒドを結合するための方法および製剤 | |
AU776019B2 (en) | Medicated chewing gum delivery system for nicotine | |
US11185526B2 (en) | Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods | |
US20240009171A1 (en) | Compositions and methods for delivery of psilocin and prodrugs thereof | |
US20090053309A1 (en) | Adhesive compositions for the treatment of xerostomia | |
FI127823B (en) | A composition for preventing the symptoms of a hangover | |
EP2349247A1 (en) | Chewing gum containing low dose amounts of water soluble vitamins | |
US20160022621A1 (en) | Composition for oral administration for binding aldehydes in the gastrointestinal tract | |
Lakkis | Encapsulation and controlled release applications in confectionery and oral care products | |
Namdev et al. | Unexplored Potential of Medicated Candies And Lozenges as a Drug Delivery System | |
EP0659077A1 (en) | Controlled release pilocarpine delivery system | |
FR2799372A1 (fr) | Enrobage de principes medicamentaux ou de produits alimentaires ou dietetiques, de nature solide, administres par voie orale, avec une composition hydrosoluble destinee a provoquer un abaissement important du ph buccal | |
JP2004002452A (ja) | アルコール性肝障害予防用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200604 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200908 |